VCP
BMRN icon

Verus Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Verus Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-363
Closed -$31K – 1481
2019
Q4 		$31K Buy
+363
New +$27.4K 0.01% 746

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Verus Capital Partners's BMRN Position: Q1 2020 in Review

Verus Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 363 shares — an estimated $31K sold.

Verus Capital Partners first reported a position in BMRN in Q4 2019 and held it in 1 quarter. The position peaked at $31K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • Verus Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Verus Capital Partners sold 363 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $31K.
  • Verus Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Verus Capital Partners's BioMarin Pharmaceuticals position peaked at $31K in Q4 2019.
  • 500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.